Cargando…
Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy
SIMPLE SUMMARY: More than half of children with high-risk neuroblastoma will not survive despite aggressive treatment regimens. The discovery of suitable novel therapies that target high-risk disease remain limited. Oncolytic virotherapy employs common viruses, such as herpes simplex virus. These vi...
Autores principales: | Quinn, Colin H., Beierle, Andee M., Hutchins, Sara Claire, Marayati, Raoud, Bownes, Laura V., Stewart, Jerry E., Markert, Hooper R., Erwin, Michael H., Aye, Jamie M., Yoon, Karina J., Friedman, Gregory K., Willey, Christopher D., Markert, James M., Beierle, Elizabeth A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834037/ https://www.ncbi.nlm.nih.gov/pubmed/35159029 http://dx.doi.org/10.3390/cancers14030762 |
Ejemplares similares
-
Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma
por: Bownes, Laura V., et al.
Publicado: (2022) -
Rapid Characterization
of Solid Tumors Using Resonant
Sensors
por: Beierle, Andee M., et al.
Publicado: (2022) -
Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor
por: Quinn, Colin H., et al.
Publicado: (2021) -
EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth
por: Bownes, Laura V., et al.
Publicado: (2021) -
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts
por: Stafman, Laura L., et al.
Publicado: (2019)